Market Overview

Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting

Share:
LEXINGTON, Mass.--(BUSINESS WIRE)--

Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held May 1-5 at the Washington State Convention Center. The presentation details are as follows:

  • Changes in intraocular pressure and conventional outflow hydrodynamics following acute topical administration of trabodenoson in living mice
    Poster #: D0159
    Authors: DS Albers, G Li, WK McVicar, and WD Stamer
    Date: Wednesday, May 4, 2016
    Time: 8:30 am to 10:15 am PDT



  • Tolerability and bioavailability of trabodenoson following local dermal administration in minipigs
    Poster #: B0239
    Authors: WK McVicar, N Kim, and DS Albers
    Date: Wednesday, May 4, 2016
    Time: 11:00 am to 12:45 pm PDT



  • Safety and tolerability of trabodenoson in non-human primates following 4 week ocular (topical) instillation
    Poster #: A0104
    Authors: CC Rich, DS Albers, R Guy, and WK McVicar
    Date: Thursday, May 5, 2016
    Time: 8:00 am to 9:45 am PDT





Inotek will have an exhibition booth set up at #1537.

About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Inotek Pharmaceuticals Corporation
Claudine Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com


View Comments and Join the Discussion!